Evelyn Fleming

648 total citations
17 papers, 145 citations indexed

About

Evelyn Fleming is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Evelyn Fleming has authored 17 papers receiving a total of 145 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Reproductive Medicine and 4 papers in Obstetrics and Gynecology. Recurrent topics in Evelyn Fleming's work include Ovarian cancer diagnosis and treatment (7 papers), PARP inhibition in cancer therapy (5 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Evelyn Fleming is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), PARP inhibition in cancer therapy (5 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Evelyn Fleming collaborates with scholars based in United States, Italy and Canada. Evelyn Fleming's co-authors include Ross S. Berkowitz, Leslie A. Garrett, Michael J. Callahan, Sue Ghosh, Donald P. Goldstein, Nicole Nevadunsky, Whitfield B. Growdon, Richard G. Moore, Gottfried E. Konecny and J Belotte and has published in prestigious journals such as Journal of Clinical Oncology, Gynecologic Oncology and Ultrasound in Medicine & Biology.

In The Last Decade

Evelyn Fleming

14 papers receiving 141 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evelyn Fleming United States 6 65 56 42 35 24 17 145
Fengxia Xue China 8 27 0.4× 31 0.6× 55 1.3× 38 1.1× 63 2.6× 22 189
Claire Hoppenot United States 7 54 0.8× 80 1.4× 14 0.3× 5 0.1× 28 1.2× 11 163
Barbara Buonomo Italy 8 130 2.0× 47 0.8× 74 1.8× 51 1.5× 26 1.1× 17 204
H. Sharif Denmark 4 46 0.7× 165 2.9× 99 2.4× 35 1.0× 11 0.5× 7 228
Joosje H. Heimovaara Belgium 5 92 1.4× 7 0.1× 20 0.5× 39 1.1× 23 1.0× 8 119
Sjarlot Kooi Netherlands 9 111 1.7× 44 0.8× 115 2.7× 41 1.2× 23 1.0× 14 290
Angela Polanco United Kingdom 5 15 0.2× 20 0.4× 24 0.6× 48 1.4× 119 5.0× 14 198
T. Tillmanns United States 4 23 0.4× 34 0.6× 17 0.4× 29 0.8× 22 0.9× 10 168
Ann O’Callaghan United Kingdom 7 65 1.0× 19 0.3× 20 0.5× 16 0.5× 25 1.0× 12 197
Ariane Weyl France 6 22 0.3× 178 3.2× 26 0.6× 7 0.2× 19 0.8× 21 260

Countries citing papers authored by Evelyn Fleming

Since Specialization
Citations

This map shows the geographic impact of Evelyn Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evelyn Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evelyn Fleming more than expected).

Fields of papers citing papers by Evelyn Fleming

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evelyn Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evelyn Fleming. The network helps show where Evelyn Fleming may publish in the future.

Co-authorship network of co-authors of Evelyn Fleming

This figure shows the co-authorship network connecting the top 25 collaborators of Evelyn Fleming. A scholar is included among the top collaborators of Evelyn Fleming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evelyn Fleming. Evelyn Fleming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Sharma, Sudarshan, Gabriel Lindahl, Lisa M. Landrum, et al.. (2025). Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up. International Journal of Gynecological Cancer. 35(2). 100243–100243.
2.
3.
4.
5.
6.
Krivak, Thomas C., Gail S. Wright, Erika Hamilton, et al.. (2022). OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecologic Oncology. 166(2). 219–229. 44 indexed citations
7.
8.
Krivak, Thomas C., Gail S. Wright, Erika Hamilton, et al.. (2021). Phase II OVARIO Study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. Gynecologic Oncology. 162. S17–S17. 13 indexed citations
9.
Krivak, Thomas C., Evelyn Fleming, Aine Clements, et al.. (2020). Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. Gynecologic Oncology. 159. 3–4. 4 indexed citations
10.
Fleming, Evelyn, et al.. (2015). 2055151 The Relationship between Clinical Symptom of Bloating and Incidence of Ovarian Neoplasm on Pelvic Ultrasound. Ultrasound in Medicine & Biology. 41(4). S105–S105. 1 indexed citations
11.
Barve, Minal, Beth A. Fine, Carolyn M. Matthews, et al.. (2015). Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: Preliminary results. Gynecologic Oncology. 137. 2–3. 3 indexed citations
12.
Litkouhi, Babak, Evelyn Fleming, William R. Welch, et al.. (2008). Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecologic Oncology. 109(2). 234–239. 14 indexed citations
13.
Orr, James W., Joseph L. Kelley, Don S. Dizon, et al.. (2008). Society of Gynecologic Oncologists Position Paper: Breast Cancer Care. Gynecologic Oncology. 110(1). 7–12. 2 indexed citations
14.
Fleming, Evelyn, Leslie A. Garrett, Whitfield B. Growdon, et al.. (2008). The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center.. PubMed. 53(7). 493–8. 40 indexed citations
15.
Gordinier, Mary E., Don S. Dizon, Evelyn Fleming, et al.. (2006). Elevated body mass index does not increase the risk of palmar–plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gynecologic Oncology. 103(1). 72–74. 11 indexed citations
16.
Fleming, Evelyn, Don S. Dizon, Paul DiSilvestro, et al.. (2004). Does body mass index predict cutaneous reactions to pegylated liposomal doxorubicin?. Journal of Clinical Oncology. 22(14_suppl). 5140–5140. 1 indexed citations
17.
Fleming, Evelyn, et al.. (1987). THE ANGELCHIK PROSTHESIS: RESULTS AND COMPLICATIONS. Australian and New Zealand Journal of Surgery. 57(9). 621–625. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fengxia Xue Breakdown of academic impact, for papers by Claire Hoppenot Breakdown of academic impact, for papers by Barbara Buonomo Breakdown of academic impact, for papers by H. Sharif Breakdown of academic impact, for papers by Joosje H. Heimovaara Breakdown of academic impact, for papers by Sjarlot Kooi Breakdown of academic impact, for papers by Angela Polanco Breakdown of academic impact, for papers by T. Tillmanns Breakdown of academic impact, for papers by Ann O’Callaghan Breakdown of academic impact, for papers by Ariane Weyl
Rankless by CCL
2026